Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.

Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, Tavakoli M, Tang T.

Int J Antimicrob Agents. 2004 Apr;23(4):315-24.

PMID:
15081078
[PubMed - indexed for MEDLINE]
2.

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.

López H, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, Vidal G, Zitto T, Tang T.

Clin Ther. 2003 Jun;25(6):1846-71.

PMID:
12860502
[PubMed - indexed for MEDLINE]
3.

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.

Wilcox M, Nathwani D, Dryden M.

J Antimicrob Chemother. 2004 Feb;53(2):335-44. Epub 2004 Jan 16.

PMID:
14729745
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.

Grau S, Mateu-de Antonio J, Soto J, Marín-Casino M, Salas E.

Pharm World Sci. 2005 Dec;27(6):459-64.

PMID:
16341954
[PubMed - indexed for MEDLINE]
5.

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.

McKinnon PS, Sorensen SV, Liu LZ, Itani KM.

Ann Pharmacother. 2006 Jun;40(6):1017-23. Epub 2006 May 23.

PMID:
16720705
[PubMed - indexed for MEDLINE]
6.

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.

Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, France AJ, Davey P.

J Antimicrob Chemother. 2003 Feb;51(2):391-6.

PMID:
12562708
[PubMed - indexed for MEDLINE]
Free Article
7.

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2005;23(9):945-64. Review.

PMID:
16153136
[PubMed - indexed for MEDLINE]
8.

Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.

Grau S, Aguado JM, Mateu-de Antonio J, Gonzalez P, Del Castillo A.

J Chemother. 2007 Aug;19(4):398-409.

PMID:
17855184
[PubMed - indexed for MEDLINE]
9.

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP.

J Antimicrob Chemother. 2004 Feb;53(2):345-55. Epub 2004 Jan 7.

PMID:
14711840
[PubMed - indexed for MEDLINE]
Free Article
11.

Pharmacoeconomics of linezolid.

Grau S, Rubio-Terrés C.

Expert Opin Pharmacother. 2008 Apr;9(6):987-1000. doi: 10.1517/14656566.9.6.987. Review.

PMID:
18377341
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.

De Cock E, Sorensen S, Levrat F, Besnier JM, Dupon M, Guery B, Duttagupta S.

Med Mal Infect. 2009 May;39(5):330-40. doi: 10.1016/j.medmal.2009.01.005. Epub 2009 Mar 21.

PMID:
19304423
[PubMed - indexed for MEDLINE]
14.

Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.

McCollum M, Rhew DC, Parodi S.

Clin Ther. 2003 Dec;25(12):3173-89.

PMID:
14749155
[PubMed - indexed for MEDLINE]
15.

[The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].

Pulay I, Konkoly TM, Zsirka KA, Csapó Z, Flautner L, Tihanyi T.

Orv Hetil. 2003 Jan 5;144(1):29-33. Hungarian.

PMID:
12635350
[PubMed - indexed for MEDLINE]
16.

[Linezolid, an agent from a new class of antibiotics].

Kuijper EJ, Schippers EF, Bernards AT.

Ned Tijdschr Geneeskd. 2004 Aug 7;148(32):1577-81. Review. Dutch.

PMID:
15382556
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.

Patanwala AE, Erstad BL, Nix DE.

Curr Med Res Opin. 2007 Jan;23(1):185-93.

PMID:
17257479
[PubMed - indexed for MEDLINE]
18.

Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.

You JH, Lee GC, So RK, Cheung KW, Hui M.

Infection. 2007 Jun;35(4):265-70. Epub 2007 Jul 23.

PMID:
17646907
[PubMed - indexed for MEDLINE]
19.

The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.

McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y.

Manag Care Interface. 2007 Jan;20(1):23-34. Erratum in: Manag Care Interface. 2007 Apr;20(4):27.

PMID:
17310650
[PubMed - indexed for MEDLINE]
20.

Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.

Tascini C, Gemignani G, Doria R, Biancofiore G, Urbani L, Mosca C, Malacarne P, Papineschi F, Passaglia C, Dal Canto L, Procaccini M, Furneri G, Didoni G, Filipponi F, Menichetti F.

J Chemother. 2009 Jun;21(3):311-6.

PMID:
19567352
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk